+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sale

COVID-19 Clinical Trials Market Research Report by Product (Therapeutics, Vaccines), Phase (Phase I, Phase II, Phase III) - United States Forecast 2023-2030

  • PDF Icon

    Report

  • 156 Pages
  • April 2023
  • Region: United States
  • 360iResearch™
  • ID: 5337382
UP TO OFF until Jun 30th 2023
The United States COVID-19 Clinical Trials Market size was estimated at USD 1,129.79 million in 2022, USD 1,281.59 million in 2023 and is projected to grow at a CAGR of 13.79% to reach USD 3,176.39 million by 2030.

Cumulative Impact of COVID-19:

COVID-19 is an unprecedented global public health emergency that affected almost every industry, and the long-term impacts are projected to reflect on the growth of various end-use industries during the forecast period. This ongoing research amplifies the research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19, considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The dedicated section in the report uncovers a detailed analysis of the impact of COVID-19 and its subsequent variant outbreaks on demand, supply, price, and vendor uptake and provides recommendations for sustainable outcomes. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the United States COVID-19 Clinical Trials Market.

Cumulative Impact of Russia-Ukraine Conflict:

The publisher continuously monitors and update reports considering unceasing political and economic uncertainty due to the Russia-Ukraine Conflict. Negative impacts are globally foreseen, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected people’s lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on Ukraine and reverberate harsh long-term effects on Russia. The report uncovers the implications for demand-supply balances, pressure on pricing variants, impact on import/export and trading, and short-term recommendations to the United States COVID-19 Clinical Trials Market considering the current update on the conflict and its global responses.

Cumulative Impact of High Inflation:

The high inflation in developed economies globally has resulted in an overall price surge over the past two years. The cumulatively eroding overall purchasing power is expected to impact developing economies significantly and is considered helpful in numerous ways. The report uncovers the effect of high inflation on the long-term performance of the global economy and provides details on fiscal policies measuring and reducing its short-term impacts on demand/supply, cash flow, and currency exchange. The United States COVID-19 Clinical Trials Market report delivers the high inflation expectation considering the related impact from cost-push and demand-pull inflation.

Market Statistics:

The report provides market sizing and forecasts across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF; multiple currency support helps organization leaders to make better decisions. In this report, 2022 as the base year, 2023 as the estimated year, and years from 2024 to 2030 are considered as the forecast period.

Market Segmentation & Coverage:

The report on the United States COVID-19 Clinical Trials Market identifies key attributes about the customer to define the potential market and identify different needs across the industry. Understanding the potential customer group's economies and geographies can help gain business acumen for better strategic decision-making. The market coverage across different industry verticals reveals the hidden truth about the players' strategies in different verticals and helps the organization decide target audience. This report gives you the composite view of sub-markets coupled with comprehensive industry coverage and provides you with the right way of accounting factors such as norms & regulations, culture, to make right coverage strategy for your market plan. This research report categorizes the United States COVID-19 Clinical Trials Market in order to forecast the revenues and analyze the trends in each of the following sub-markets:
  • Based on Product, the market is studied across Therapeutics and Vaccines.
  • Based on Phase, the market is studied across Phase I, Phase II, Phase III, and Phase IV.
  • Based on State, the market is studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas.

FPNV Positioning Matrix:

The FPNV Positioning Matrix evaluates and categorizes vendors in the United States COVID-19 Clinical Trials Market. based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) and placed into four quadrants (F: Forefront, P: Pathfinder, N: Niche, and V: Vital). The United States COVID-19 Clinical Trials Market FPNV Positioning Matrix representation/visualization further aids businesses in better decision-making and understanding the competitive landscape.

Market Share Analysis:

The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market, providing the idea of revenue generation into the overall market compared to other vendors in the space. This provides insights on vendors performance in terms of revenue generation and customer base compared to others. The United States COVID-19 Clinical Trials Market Share Analysis offers an idea of the size and competitiveness of the vendors for the base year. The outcome reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

Competitive Scenario:

The Competitive Scenario provides an outlook analysis of the various strategies for business growth adopted by the vendors. The news in this section covers valuable insights at various stages while keeping up with the business and engaging stakeholders in the economic debate. The United States COVID-19 Clinical Trials Market Competitive Scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected helps vendors understand the gaps in the marketplace and competitor’s strengths and weaknesses, providing insights to enhance products and services.

Company Usability Profiles:

The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the United States COVID-19 Clinical Trials Market, including AbbVie Inc., Bharat Biotech Ltd., BioNTech SE, Clario, Gilead Sciences, Inc., GlaxoSmithKline PLC, ICON PLC, Inovio Pharmaceuticals, Inc., IQVIA Inc., Johnson & Johnson Services, Inc., Laboratory Corporation of America Holdings, Medidata Solutions, Moderna, Inc., Novartis AG, Novavax, Inc., Novotech, PAREXEL International Corporation, Pfizer Inc., PPD, Inc., Quanticate, and Takeda Pharmaceutical Company Limited.

The report provides insights on the following pointers:

1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Market Trends: Provides comprehensive understanding of the Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and the High Inflation
5. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
6. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

1. What is the market size and forecast of the United States COVID-19 Clinical Trials Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the United States COVID-19 Clinical Trials Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the United States COVID-19 Clinical Trials Market?
4. What is the competitive strategic window for opportunities in the United States COVID-19 Clinical Trials Market?
5. What are the technology trends and regulatory frameworks in the United States COVID-19 Clinical Trials Market?
6. What is the market share of the leading vendors in the United States COVID-19 Clinical Trials Market?
7. What modes and strategic moves are considered suitable for entering the United States COVID-19 Clinical Trials Market?
Frequently Asked Questions about the U.S. COVID-19 Clinical Trials Market

What is the estimated value of the U.S. COVID-19 Clinical Trials Market?

The U.S. COVID-19 Clinical Trials Market was estimated to be valued at $1129.79 Million in 2022.

What is the growth rate of the U.S. COVID-19 Clinical Trials Market?

The growth rate of the U.S. COVID-19 Clinical Trials Market is 13.7%, with an estimated value of $3176.39 Million by 2030.

What is the forecasted size of the U.S. COVID-19 Clinical Trials Market?

The U.S. COVID-19 Clinical Trials Market is estimated to be worth $3176.39 Million by 2030.

Who are the key companies in the U.S. COVID-19 Clinical Trials Market?

Key companies in the U.S. COVID-19 Clinical Trials Market include AbbVie Inc., Bharat Biotech Ltd., BioNTech SE, Clario, Gilead Sciences, Inc., GlaxoSmithKline PLC, ICON PLC, Inovio Pharmaceuticals, Inc., IQVIA Inc. and Johnson & Johnson Services, Inc..

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increasing number of COVID-19 cases and rising number of deaths
5.1.1.2. Government support and grants for COVID-19 clinical trials
5.1.2. Restraints
5.1.2.1. Complexities in clinical trial management and risk of side effects during trials
5.1.3. Opportunities
5.1.3.1. Increasing research and development initiatives for effective COVID-19 therapeutics
5.1.4. Challenges
5.1.4.1. Limited availability of trained medical professionals
5.2. Cumulative Impact of COVID-19
5.3. Cumulative Impact of Russia-Ukraine Conflict
5.4. Cumulative Impact of High Inflation
5.5. Porter’s Five Forces Analysis
5.5.1. Threat of New Entrants
5.5.2. Threat of Substitutes
5.5.3. Threat of Substitutes
5.5.4. Threat of Substitutes
5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework
5.8. Client Customization
6. COVID-19 Clinical Trials Market, by Product
6.1. Introduction
6.2. Therapeutics
6.3. Vaccines
7. COVID-19 Clinical Trials Market, by Phase
7.1. Introduction
7.2. Phase I
7.3. Phase II
7.4. Phase III
7.5. Phase IV
8. California COVID-19 Clinical Trials Market
8.1. Introduction
9. Florida COVID-19 Clinical Trials Market
9.1. Introduction
10. Illinois COVID-19 Clinical Trials Market
10.1. Introduction
11. New York COVID-19 Clinical Trials Market
11.1. Introduction
12. Ohio COVID-19 Clinical Trials Market
12.1. Introduction
13. Pennsylvania COVID-19 Clinical Trials Market
13.1. Introduction
14. Texas COVID-19 Clinical Trials Market
14.1. Introduction
15. Competitive Landscape
15.1. FPNV Positioning Matrix
15.1.1. Quadrants
15.1.2. Business Strategy
15.1.3. Product Satisfaction
15.2. Market Ranking Analysis, By Key Player
15.3. Market Share Analysis, By Key Player
15.4. Product Portfolio Analysis, By Key Player
15.5. Competitive Scenario
15.5.1. Merger & Acquisition
15.5.2. Agreement, Collaboration, & Partnership
15.5.3. New Product Launch & Enhancement
15.5.4. Investment & Funding
15.5.5. Award, Recognition, & Expansion
16. Company Usability Profiles
16.1. AbbVie Inc.
16.2. Bharat Biotech Ltd.
16.3. BioNTech SE
16.4. Clario
16.5. Gilead Sciences, Inc.
16.6. GlaxoSmithKline PLC
16.7. ICON PLC
16.8. Inovio Pharmaceuticals, Inc.
16.9. IQVIA Inc.
16.10. Johnson & Johnson Services, Inc.
16.11. Laboratory Corporation of America Holdings
16.12. Medidata Solutions
16.13. Moderna, Inc.
16.14. Novartis AG
16.15. Novavax, Inc.
16.16. Novotech
16.17. PAREXEL International Corporation
16.18. Pfizer Inc.
16.19. PPD, Inc.
16.20. Quanticate
16.21. Takeda Pharmaceutical Company Limited
17. Appendix
17.1. Discussion Guide
17.2. License & Pricing
List of Figures
FIGURE 1. UNITED STATES COVID-19 CLINICAL TRIALS MARKET: RESEARCH PROCESS
FIGURE 2. UNITED STATES COVID-19 CLINICAL TRIALS MARKET SIZE, 2022 VS 2030
FIGURE 3. UNITED STATES COVID-19 CLINICAL TRIALS MARKET SIZE, 2022-2030 (USD MILLION)
FIGURE 4. UNITED STATES COVID-19 CLINICAL TRIALS MARKET SIZE, BY STATE, 2022 VS 2030 (%)
FIGURE 5. UNITED STATES COVID-19 CLINICAL TRIALS MARKET SIZE, BY STATE, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 6. UNITED STATES COVID-19 CLINICAL TRIALS MARKET COMPETITIVE STRATEGIC WINDOW, BY STATE, 2030
FIGURE 7. UNITED STATES COVID-19 CLINICAL TRIALS MARKET DYNAMICS
FIGURE 8. UNITED STATES COVID-19 CLINICAL TRIALS MARKET PORTER’S FIVE FORCES ANALYSIS
FIGURE 9. UNITED STATES COVID-19 CLINICAL TRIALS MARKET SIZE, BY PRODUCT, 2022 VS 2030 (%)
FIGURE 10. UNITED STATES COVID-19 CLINICAL TRIALS MARKET SIZE, BY PRODUCT, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 11. UNITED STATES COVID-19 CLINICAL TRIALS MARKET COMPETITIVE STRATEGIC WINDOW, BY PRODUCT, 2030
FIGURE 12. UNITED STATES COVID-19 CLINICAL TRIALS MARKET SIZE, BY THERAPEUTICS, 2022-2030 (USD MILLION)
FIGURE 13. UNITED STATES COVID-19 CLINICAL TRIALS MARKET SIZE, BY VACCINES, 2022-2030 (USD MILLION)
FIGURE 14. UNITED STATES COVID-19 CLINICAL TRIALS MARKET SIZE, BY PHASE, 2022 VS 2030 (%)
FIGURE 15. UNITED STATES COVID-19 CLINICAL TRIALS MARKET SIZE, BY PHASE, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 16. UNITED STATES COVID-19 CLINICAL TRIALS MARKET COMPETITIVE STRATEGIC WINDOW, BY PHASE, 2030
FIGURE 17. UNITED STATES COVID-19 CLINICAL TRIALS MARKET SIZE, BY PHASE I, 2022-2030 (USD MILLION)
FIGURE 18. UNITED STATES COVID-19 CLINICAL TRIALS MARKET SIZE, BY PHASE II, 2022-2030 (USD MILLION)
FIGURE 19. UNITED STATES COVID-19 CLINICAL TRIALS MARKET SIZE, BY PHASE III, 2022-2030 (USD MILLION)
FIGURE 20. UNITED STATES COVID-19 CLINICAL TRIALS MARKET SIZE, BY PHASE IV, 2022-2030 (USD MILLION)
FIGURE 21. CALIFORNIA COVID-19 CLINICAL TRIALS MARKET SIZE, 2022-2030 (USD MILLION)
FIGURE 22. FLORIDA COVID-19 CLINICAL TRIALS MARKET SIZE, 2022-2030 (USD MILLION)
FIGURE 23. ILLINOIS COVID-19 CLINICAL TRIALS MARKET SIZE, 2022-2030 (USD MILLION)
FIGURE 24. NEW YORK COVID-19 CLINICAL TRIALS MARKET SIZE, 2022-2030 (USD MILLION)
FIGURE 25. OHIO COVID-19 CLINICAL TRIALS MARKET SIZE, 2022-2030 (USD MILLION)
FIGURE 26. PENNSYLVANIA COVID-19 CLINICAL TRIALS MARKET SIZE, 2022-2030 (USD MILLION)
FIGURE 27. TEXAS COVID-19 CLINICAL TRIALS MARKET SIZE, 2022-2030 (USD MILLION)
FIGURE 28. UNITED STATES COVID-19 CLINICAL TRIALS MARKET: FPNV POSITIONING MATRIX, 2022
FIGURE 29. UNITED STATES COVID-19 CLINICAL TRIALS MARKET SHARE, BY KEY PLAYER, 2022
FIGURE 30. UNITED STATES COVID-19 CLINICAL TRIALS MARKET COMPETITIVE SCENARIO, BY KEY TYPE, 2022
List of Tables
TABLE 1. UNITED STATES COVID-19 CLINICAL TRIALS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2022-2022
TABLE 3. UNITED STATES COVID-19 CLINICAL TRIALS MARKET SIZE, 2022-2030 (USD MILLION)
TABLE 4. UNITED STATES COVID-19 CLINICAL TRIALS MARKET SIZE, BY STATE, 2022-2030 (USD MILLION)
TABLE 5. UNITED STATES COVID-19 CLINICAL TRIALS MARKET SIZE, BY PRODUCT, 2022-2030 (USD MILLION)
TABLE 6. UNITED STATES COVID-19 CLINICAL TRIALS MARKET SIZE, BY THERAPEUTICS, 2022-2030 (USD MILLION)
TABLE 7. UNITED STATES COVID-19 CLINICAL TRIALS MARKET SIZE, BY THERAPEUTICS, BY STATE, 2022-2030 (USD MILLION)
TABLE 8. UNITED STATES COVID-19 CLINICAL TRIALS MARKET SIZE, BY VACCINES, 2022-2030 (USD MILLION)
TABLE 9. UNITED STATES COVID-19 CLINICAL TRIALS MARKET SIZE, BY VACCINES, BY STATE, 2022-2030 (USD MILLION)
TABLE 10. UNITED STATES COVID-19 CLINICAL TRIALS MARKET SIZE, BY PHASE, 2022-2030 (USD MILLION)
TABLE 11. UNITED STATES COVID-19 CLINICAL TRIALS MARKET SIZE, BY PHASE I, 2022-2030 (USD MILLION)
TABLE 12. UNITED STATES COVID-19 CLINICAL TRIALS MARKET SIZE, BY PHASE I, BY STATE, 2022-2030 (USD MILLION)
TABLE 13. UNITED STATES COVID-19 CLINICAL TRIALS MARKET SIZE, BY PHASE II, 2022-2030 (USD MILLION)
TABLE 14. UNITED STATES COVID-19 CLINICAL TRIALS MARKET SIZE, BY PHASE II, BY STATE, 2022-2030 (USD MILLION)
TABLE 15. UNITED STATES COVID-19 CLINICAL TRIALS MARKET SIZE, BY PHASE III, 2022-2030 (USD MILLION)
TABLE 16. UNITED STATES COVID-19 CLINICAL TRIALS MARKET SIZE, BY PHASE III, BY STATE, 2022-2030 (USD MILLION)
TABLE 17. UNITED STATES COVID-19 CLINICAL TRIALS MARKET SIZE, BY PHASE IV, 2022-2030 (USD MILLION)
TABLE 18. UNITED STATES COVID-19 CLINICAL TRIALS MARKET SIZE, BY PHASE IV, BY STATE, 2022-2030 (USD MILLION)
TABLE 19. CALIFORNIA COVID-19 CLINICAL TRIALS MARKET SIZE, 2022-2030 (USD MILLION)
TABLE 20. CALIFORNIA COVID-19 CLINICAL TRIALS MARKET SIZE, BY PRODUCT, 2022-2030 (USD MILLION)
TABLE 21. CALIFORNIA COVID-19 CLINICAL TRIALS MARKET SIZE, BY PHASE, 2022-2030 (USD MILLION)
TABLE 22. FLORIDA COVID-19 CLINICAL TRIALS MARKET SIZE, 2022-2030 (USD MILLION)
TABLE 23. FLORIDA COVID-19 CLINICAL TRIALS MARKET SIZE, BY PRODUCT, 2022-2030 (USD MILLION)
TABLE 24. FLORIDA COVID-19 CLINICAL TRIALS MARKET SIZE, BY PHASE, 2022-2030 (USD MILLION)
TABLE 25. ILLINOIS COVID-19 CLINICAL TRIALS MARKET SIZE, 2022-2030 (USD MILLION)
TABLE 26. ILLINOIS COVID-19 CLINICAL TRIALS MARKET SIZE, BY PRODUCT, 2022-2030 (USD MILLION)
TABLE 27. ILLINOIS COVID-19 CLINICAL TRIALS MARKET SIZE, BY PHASE, 2022-2030 (USD MILLION)
TABLE 28. NEW YORK COVID-19 CLINICAL TRIALS MARKET SIZE, 2022-2030 (USD MILLION)
TABLE 29. NEW YORK COVID-19 CLINICAL TRIALS MARKET SIZE, BY PRODUCT, 2022-2030 (USD MILLION)
TABLE 30. NEW YORK COVID-19 CLINICAL TRIALS MARKET SIZE, BY PHASE, 2022-2030 (USD MILLION)
TABLE 31. OHIO COVID-19 CLINICAL TRIALS MARKET SIZE, 2022-2030 (USD MILLION)
TABLE 32. OHIO COVID-19 CLINICAL TRIALS MARKET SIZE, BY PRODUCT, 2022-2030 (USD MILLION)
TABLE 33. OHIO COVID-19 CLINICAL TRIALS MARKET SIZE, BY PHASE, 2022-2030 (USD MILLION)
TABLE 34. PENNSYLVANIA COVID-19 CLINICAL TRIALS MARKET SIZE, 2022-2030 (USD MILLION)
TABLE 35. PENNSYLVANIA COVID-19 CLINICAL TRIALS MARKET SIZE, BY PRODUCT, 2022-2030 (USD MILLION)
TABLE 36. PENNSYLVANIA COVID-19 CLINICAL TRIALS MARKET SIZE, BY PHASE, 2022-2030 (USD MILLION)
TABLE 37. TEXAS COVID-19 CLINICAL TRIALS MARKET SIZE, 2022-2030 (USD MILLION)
TABLE 38. TEXAS COVID-19 CLINICAL TRIALS MARKET SIZE, BY PRODUCT, 2022-2030 (USD MILLION)
TABLE 39. TEXAS COVID-19 CLINICAL TRIALS MARKET SIZE, BY PHASE, 2022-2030 (USD MILLION)
TABLE 40. UNITED STATES COVID-19 CLINICAL TRIALS MARKET: FPNV POSITIONING MATRIX - SCORES, 2022
TABLE 41. UNITED STATES COVID-19 CLINICAL TRIALS MARKET: FPNV POSITIONING MATRIX - BUSINESS STRATEGY, 2022
TABLE 42. UNITED STATES COVID-19 CLINICAL TRIALS MARKET: FPNV POSITIONING MATRIX - PRODUCT SATISFACTION, 2022
TABLE 43. UNITED STATES COVID-19 CLINICAL TRIALS MARKET RANKING, BY KEY PLAYER, 2022
TABLE 44. UNITED STATES COVID-19 CLINICAL TRIALS MARKET SHARE, BY KEY PLAYER, 2022
TABLE 45. UNITED STATES COVID-19 CLINICAL TRIALS MARKET PRODUCT PORTFOLIO ANALYSIS, BY KEY PLAYER, 2022
TABLE 46. UNITED STATES COVID-19 CLINICAL TRIALS MARKET MERGER & ACQUISITION
TABLE 47. UNITED STATES COVID-19 CLINICAL TRIALS MARKET AGREEMENT, COLLABORATION, & PARTNERSHIP
TABLE 48. UNITED STATES COVID-19 CLINICAL TRIALS MARKET NEW PRODUCT LAUNCH & ENHANCEMENT
TABLE 49. UNITED STATES COVID-19 CLINICAL TRIALS MARKET INVESTMENT & FUNDING
TABLE 50. UNITED STATES COVID-19 CLINICAL TRIALS MARKET AWARD, RECOGNITION, & EXPANSION
TABLE 51. UNITED STATES COVID-19 CLINICAL TRIALS MARKET: LICENSE & PRICING

Companies Mentioned

  • AbbVie Inc.
  • Bharat Biotech Ltd.
  • BioNTech SE
  • Clario
  • Gilead Sciences, Inc.
  • GlaxoSmithKline PLC
  • ICON PLC
  • Inovio Pharmaceuticals, Inc.
  • IQVIA Inc.
  • Johnson & Johnson Services, Inc.
  • Laboratory Corporation of America Holdings
  • Medidata Solutions
  • Moderna, Inc.
  • Novartis AG
  • Novavax, Inc.
  • Novotech
  • PAREXEL International Corporation
  • Pfizer Inc.
  • PPD, Inc.
  • Quanticate
  • Takeda Pharmaceutical Company Limited

Methodology

Loading
LOADING...